Portfolio Highlights and 2026 Milestones:...Velinotamig (BCMAxCD3 bispecific T cell engager) (GlobeNewswire) - Mar 10, 2026 - "Genrix Bio is enrolling a Phase 1 study in China in patients with autoimmune diseases, initially in patients with SLE, followed by future planned expansion into other indications and initial clinical data from the study are expected to be shared in Q4 2026....Following completion of the Genrix Bio Phase 1 study, Cullinan will conduct all further development of velinotamig in autoimmune diseases."
Enrollment status • P1 data • Pipeline update • Systemic Lupus Erythematosus
|